Physician profile
Kefu Du
NPI 1326346388
$2,825.50
in general payments reported to CMS, 2019-2025
13 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $97.18 · 2021: $34.82 · 2022: $187 · 2023: $470 · 2024: $849 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $732.03 | 2021-2025 | Speedicath, Surecath |
| Boston Scientific Corporation | $612.57 | 2019-2025 | Lithovue, Lithoclast, General - Kidney Stone Disease |
| Calyxo, INC. | $401.13 | 2024-2025 | Cvac Aspiration System |
| Intuitive Surgical, INC. | $241.55 | 2019-2023 | |
| Urogen Pharma, INC. | $234.69 | 2024 | |
| Tempus Ai, INC | $155.92 | 2024 | |
| Janssen Scientific Affairs, LLC | $115.03 | 2025 | Erleada |
| C. R. Bard, INC. & Subsidiaries | $110.02 | 2019 | |
| Janssen Biotech, INC. | $88.65 | 2025 | Erleada |
| Karl Storz Endoscopy-America | $54.68 | 2024 | N.A. |
| Myriad Genetic Laboratories, INC. | $36.90 | 2023 | Prolaris |
| Merck Sharp & Dohme LLC | $24.40 | 2025 | Keytruda, Welireg |
| Kci USA, INC. | $17.93 | 2023 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kefu Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.